Compare LARK & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | CNTN |
|---|---|---|
| Founded | 1885 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 178.5M |
| IPO Year | 2001 | 2021 |
| Metric | LARK | CNTN |
|---|---|---|
| Price | $31.27 | $2.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.0K | ★ 731.6K |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | 35.84 | ★ 88.10 |
| EPS | ★ 1.70 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.57 | $1.75 |
| 52 Week High | $34.60 | $5.27 |
| Indicator | LARK | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 44.70 |
| Support Level | $30.94 | $2.09 |
| Resistance Level | $32.40 | $2.40 |
| Average True Range (ATR) | 0.45 | 0.18 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 26.22 | 10.14 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.